How Type 2 Inflammation Influences Treatment Choices

Panelists discuss how identifying type 2 inflammation in patients influences treatment decisions by steering clinicians toward targeted therapies, such as biologics or other immunomodulators, that specifically address the underlying inflammatory mechanisms rather than relying solely on symptomatic treatments.

EP: 1.Navigating the Challenges of Respiratory Diseases

EP: 2.The Impact of Atopic Dermatitis and Prurigo Nodularis

EP: 3.Linking Type 2 Inflammation to Asthma and COPD

EP: 4.Impact of Exacerbations in Type 2 Inflammatory Respiratory Diseases

EP: 5.Type 2 Inflammation: The Link Between AD and PN

EP: 6.Personalizing Treatment Selection

EP: 7.Navigating Treatment Challenges in Chronic Skin Conditions

EP: 8.Role of Biologics in Dermatological Care

EP: 9.Biomarkers as Tools in Management of Type 2 Inflammation

EP: 10.Strategies to Manage Type 2 Inflammation in Respiratory Diseases

EP: 11.Addressing Unmet Needs and Emerging Agents

EP: 12.Future Directions for Type 2 Inflammation Management

EP: 13.Type 2 Inflammatory Diseases and Impact on Quality of Life

EP: 14.Type 2 Inflammation Biomarkers

Now Viewing

EP: 15.How Type 2 Inflammation Influences Treatment Choices

EP: 16.Complications of Uncontrolled Disease and Management of Comorbidities

EP: 17.Patient Education and Emerging Therapies

EP: 18.Unmet Needs and Future Research

• In your experience, how does knowing a patient has type 2 inflammation influence the choice in treatment?

Related Videos

Related Content

Advertisement

August 14th 2025

Temporal Shift in Prevalence of Heart Failure Diagnoses and Comorbidities Within 2 US Integrated Health Systems

Mario Enrico Canonico, MD, PhD Judith Hsia, MD Shih-Ting Chiu, PhD Pu-Kai Tseng James O. Mudd, MD Joshua D. Remick, MD Bansi Patel, MS Ya-Hsiu Chuang, PhD Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Marc P. Bonaca, MD, MPH

August 14th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

August 14th 2025

Assessment of Variation in Ambulatory Cardiac Monitoring Among Commercially Insured Patients

Pierantonio Russo, MD Henriette Coetzer, MD Erik M. Hendrickson, PhD Kenneth Boyle, DC Brent Wright, DrPH

August 14th 2025

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

August 14th 2025

Care Quality Metrics in Medicare During COVID-19 Pandemic

Jeanette Thornton, MPA Mark Hamelburg, JD Lynn Nonnemaker, PhD Sherzod Abdukadirov, PhD German Veselovskiy, MPP Sari Siegel, PhD

August 14th 2025

Switching Biologics in Psoriasis Boosts Effectiveness but Raises Infection Risk

Pearl Steinzor

Related Content

Advertisement

August 14th 2025

Temporal Shift in Prevalence of Heart Failure Diagnoses and Comorbidities Within 2 US Integrated Health Systems

Mario Enrico Canonico, MD, PhD Judith Hsia, MD Shih-Ting Chiu, PhD Pu-Kai Tseng James O. Mudd, MD Joshua D. Remick, MD Bansi Patel, MS Ya-Hsiu Chuang, PhD Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Marc P. Bonaca, MD, MPH

August 14th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

August 14th 2025

Assessment of Variation in Ambulatory Cardiac Monitoring Among Commercially Insured Patients

Pierantonio Russo, MD Henriette Coetzer, MD Erik M. Hendrickson, PhD Kenneth Boyle, DC Brent Wright, DrPH

August 14th 2025

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

August 14th 2025

Care Quality Metrics in Medicare During COVID-19 Pandemic

Jeanette Thornton, MPA Mark Hamelburg, JD Lynn Nonnemaker, PhD Sherzod Abdukadirov, PhD German Veselovskiy, MPP Sari Siegel, PhD

August 14th 2025

Switching Biologics in Psoriasis Boosts Effectiveness but Raises Infection Risk

Pearl Steinzor